Skip to Content

Generic Vibativ Availability

Vibativ is a brand name of telavancin, approved by the FDA in the following formulation(s):

VIBATIV (telavancin hydrochloride - powder;iv (infusion))

  • Manufacturer: THERAVANCE BIOPHARMA
    Approval date: September 11, 2009
    Strength(s): EQ 250MG BASE/VIAL, EQ 750MG BASE/VIAL [RLD]

Has a generic version of Vibativ been approved?

No. There is currently no therapeutically equivalent version of Vibativ available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vibativ. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Glycopeptide phosphonate derivatives
    Patent 6,635,618
    Issued: October 21, 2003
    Inventor(s): Michael R.; Leadbetter & Martin S.; Linsell
    Assignee(s): Theravance, Inc.
    Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
    Patent expiration dates:
    • September 11, 2023
      ✓ 
      Patent use: METHOD FOR TREATING BACTERIAL INFECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
    Patent 6,858,584
    Issued: February 22, 2005
    Inventor(s): Judice; J. Kevin & Shaw; Jeng-Pyng & Mu; YongQi & Conner; Michael W. & Pace; John L.
    Assignee(s): Theravance, Inc.
    Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
    Patent expiration dates:
    • August 24, 2022
      ✓ 
      Drug product
  • Glycopeptide phosphonate derivatives
    Patent 6,872,701
    Issued: March 29, 2005
    Inventor(s): Leadbetter; Michael R. & Linsell; Martin S.
    Assignee(s): Theravance, Inc.
    Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
    Patent expiration dates:
    • June 5, 2021
      ✓ 
      Drug product
  • Glycopeptide phosphonate derivatives
    Patent 7,008,923
    Issued: March 7, 2006
    Inventor(s): Leadbetter; Michael R. & Linsell; Martin S.
    Assignee(s): Theravance, Inc.
    Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
    Patent expiration dates:
    • May 6, 2021
      ✓ 
      Patent use: METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
  • Glycopeptide phosphonate derivatives
    Patent 7,208,471
    Issued: April 24, 2007
    Inventor(s): Leadbetter; Michael R.
    Assignee(s): Theravance, Inc.
    Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
    Patent expiration dates:
    • May 1, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Glycopeptide phosphonate derivatives
    Patent 7,351,691
    Issued: April 1, 2008
    Inventor(s): Leadbetter; Michael R. & Linsell; Martin S.
    Assignee(s): Theravance, Inc.
    Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
    Patent expiration dates:
    • May 1, 2021
      ✓ 
      Patent use: METHOD FOR TREATING BACTERIAL INFECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Hydrochloride salts of a glycopeptide phosphonate derivative
    Patent 7,531,623
    Issued: May 12, 2009
    Inventor(s): Liu; Jyanwei & Lee; Junning
    Assignee(s): Theravance, Inc.
    Disclosed are hydrochloride salts of telavancin having a chloride ion content of from about 2.4 wt. % to about 4.8 wt. %. The disclosed salts have improved stability during storage at ambient temperatures compared to other hydrochloride salts. Also disclosed are processes for preparing such salts.
    Patent expiration dates:
    • January 1, 2027
      ✓ 
      Drug substance
  • Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
    Patent 7,544,364
    Issued: June 9, 2009
    Inventor(s): Judice; J. Kevin & Shaw; Jeng-Pyng & Mu; YongQi & Conner; Michael W. & Pace; John L.
    Assignee(s): Theravance, Inc.
    Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
    Patent expiration dates:
    • May 1, 2021
      ✓ 
      Drug product
  • Glycopeptide phosphonate derivatives
    Patent 7,700,550
    Issued: April 20, 2010
    Inventor(s): Leadbetter; Michael R.
    Assignee(s): Theravance, Inc.
    Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
    Patent expiration dates:
    • May 1, 2021
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  • Glycopeptide phosphonate derivatives
    Patent 8,101,575
    Issued: January 24, 2012
    Inventor(s): Leadbetter; Michael R.
    Assignee(s): Theravance, Inc.
    Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
    Patent expiration dates:
    • May 1, 2021
      ✓ 
      Drug product
  • Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
    Patent 8,158,580
    Issued: April 17, 2012
    Inventor(s): Judice; J. Kevin & Shaw; Jeng-Pyng & Mu; YongQi & Conner; Michael W. & Pace; John L.
    Assignee(s): Theravance, Inc.
    Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
    Patent expiration dates:
    • May 1, 2021
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 21, 2016 - TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide